Sign in to view content

Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes

Carl D. Regillo, MD

Video
Published 2022

Related

A Comparison of the Anatomical Efficacy of Brolucizumab Versus Aflibercept in nAMD Patients: Matched 16-Week Results From the HAWK and HARRIER Studies
Pravin U. Dugel, MD
Annual Meeting Talks
2018
Association Between Dysfunctional Complement Factor I: Rare Variant Status and Progression to Advanced AMD Outcomes
Johanna M. Seddon, MD, ScM, FARVO, FASRS
Annual Meeting Talks
2022
Charlson Comorbidity Index As a Predictive Tool in Patients With Exudative Age-Related Macular Degeneration in Delay of Care
Vivienne S. Hau, MD, PhD
Annual Meeting Talks
2024

Category: AMD-Neovascular

See more